ClinicalTrials.gg
CompletedNCT01145339EF099Updated Jun 26, 2012

A Non-inferiority, Multicenter and Randomized, Single-Dose Study About a Treatment to Hypolactasia (LAILAI)

A Phase 3 interventional study of Lactase in Hypolactasia, sponsored by Eurofarma Laboratorios S.A.. Completed at 7 sites in Brazil. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2012-06-26.

Sponsored by Eurofarma Laboratorios S.A. · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The study primary objective is to compare the clinical efficacy of two formulations in the supportive treatment of lactose intolerance.

02

Conditions studied

  • Hypolactasia

Browse trials for

03

In context

Lactose Intolerance

53 studies on the registry are indexed under Lactose Intolerance; 6 are open to participants now.

This study's enrollment of 140 is above the median of 41 across 41 interventional studies indexed under Lactose Intolerance.

Browse Lactose Intolerance studies →

Lead sponsor

Eurofarma Laboratorios S.A. is the lead sponsor of 64 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient should be a male or female, aged between 18 and 60 years old;
  2. Have a medical history consistent with lactose intolerance, confirmed by the test of hydrogen in the expired air;
  3. The female patients should agree to use methods during the study participation;
  4. To be able to meet the study instructions and all the visits required;
  5. To give a free consent to participate in the study and sign the form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. Smoking;
  2. Secondary hypolactasia;
  3. Gastrointestinal inflammatories diseases - present diverticular disease, diabetic gastropathy or neoplasias;
  4. Colonoscopy or colon cleaning procedure 4 weeks before the start of study
  5. Latrogenic: unnoticed intake of laxatives in over-the-counter drugs or alternative medicine, intake of cereal bran or probiotics;
  6. Diagnosis of , immunodepression of any origin, or cancer under treatment.
  7. Diagnosis of other comorbidity that, at the investigator's discretion, may compromise the study participation (e.g., systemic infection during the study or use of antibiotics in the last 4 weeks, diabetes mellitus, uncontrolled hypertension or renal failure),
  8. or previous laboratory or clinical adverse event related to the use of lactase or any of the components of the formulations used in the study;
  9. Incapacity to understand and complete the study questionnaires, including the questions that require the use of the Visual Analogue Scale and ICF;
  10. Pregnancy or lactation;
  11. Use of alcohol, exceeding 3 doses daily;
  12. Participation in another clinical study on the last 12 months;
  13. Patient having some chronic pulmonary disease that, in the investigator's opinion, may harm or interfere with the expired hydrogen test (e.g., cystic fibrosis).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Lactase EUF

    1 chewable tablet of the test drug 30 minutes before the standard lactose dose (25 g).

    Drug: Lactase

  • Active comparator
    Lactase Ref

    1 chewable tablet of the comparative drug 30 minutes before the standard lactose dose (25 g).

    Drug: Lactase

Interventions

  • 1 chewable tablet of the test drug or comparative drug 30 minutes before the standard lactose dose (25 g).

06

What researchers measure

Primary outcomes

  1. Hydrogen value in the air expired

    Hydrogen value in the expired air for 3h after the patient exposure to the standardized Lactose 25g dose with interventional exogenous Lactase (comparative and test drugs).

    Time frame: 03 times

07

Study locations

7 sites
  • Instituto Goiano de Gastroenterologia
    Goiania, GO, Brazil
  • Instituto Alfa de Gastroenterologia
    Belo Horizonte, MG, Brazil
  • Hospital Nossa Senhora das Graças
    Curitiba, PR, Brazil
  • Hospital São Lucas
    Porto Alegre, RS 90610-000, Brazil
  • Hospital Mãe de Deus
    Porto Alegre, RS, Brazil
  • Faculdade de Medicina do ABC
    Santo André, SP, Brazil
  • Hospital São Paulo / UNIFESP
    São Paulo, SP, Brazil
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Nov 2011 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2010
First posted
Jun 16, 2010
Start
Jul 2011
Primary completionActual
Nov 2011
CompletionActual
Mar 2012
Last update
Jun 26, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01145339
Responsible party
Sponsor
First posted
Jun 16, 2010
Start date
Jul 2011
Primary completion
Nov 2011
Completion
Mar 2012
Last update
Jun 26, 2012

Study contacts

Aderson Damião, M.D
principal investigator · Hospital das Clínicas de São Paulo
Heda Amarante, M.D
principal investigator · Hospital Nossa Senhora das Graças
Marta Machado, M.D
principal investigator · Hospital São Lucas PUCRS
Sender Miszputen, M.D
principal investigator · Hospital São Paulo / UNIFESP
Wilson Catapani, M.D
principal investigator · Faculdade de Medicina do ABC
Mauro Bafutto, M.D
principal investigator · Instituto Goiano de Gastroenterologia
Carlos Francesconi, M.D
principal investigator · Hospital Mãe de Deus
Maria do Carmo Passos, M.D
principal investigator · Instituto Alfa de Gastroenterologia de BH

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lactase

Start the discussion